

BUY
TP: Rs 13,137 | A 30%

ULTRATECH CEMENT

Cement

01 March 2025

Diversification Play; Sharp focus on Cement Stays, Retain BUY

- UTCEM allocates Rs18bn (~2% of capital allocation) in the building material value chain by investing in wire and cable business
- Sharp focus on cement stays with target to achieve 209mnt domestic cement capacity by FY27 implying ~27% of the industry capacity
- EBITDA estimates retained for FY25E/FY26E/FY27E; expect new stream to contribute from FY28, Maintain BUY with unchanged TP of Rs13,137

Milind Raginwar research@bobcaps.in

UTCEM allocates Rs18bn to enter wires and cable business: UTCEM has received board approval to invest Rs18bn in the wires and cable business through its building product division. The investment is in line with the UTCEM's strategy to strengthen its position as a comprehensive building solutions provider. The investment will be in the next 2 years. UTCEM will expand its presence in the construction value chain through the foray in the cables and wires segment.

Entry in the new business stream through green field expansion: UTCEM intends to enter the W & C business with investment in the green field project (plant) at Jhagadia, near Bharuch in Gujarat with a total capacity of 3.5/4.0 mn kms. The key product categories will be Wires and various cable categories. The plant is expected to be operational by Q3FY27.

Expect to tap pan-India footprint; maintain industry margins: UTCEM plans to leverage the existing channel network to tap pan-India presence in the wire and cable network. The initial revenue focus will be 60:40 for the wire & cable segment. UTCEM indicated it will maintain the industry EBITDA margins (~10-11%) with a return ratio profile of upwards of 20% (~25%).

Cement focus continues to sharpen: UTCEM's current cement capacity (FY25-end) is expected to be 182.8mnt and it intends to expand its domestic reach to ~209mnt by FY27. The growth pace of the company is ahead of the industry growth in adding capacities and UTCEM will be ~27% of the total industry capacity in FY27.

Maintain earnings estimates, Retain BUY rating: We feel UTCEM's entry in the new business of W & C is to extend the building material value chain by offering one-stop solution. The initial investment of Rs18bn spread over next 2 years is a diversification of capital allocation but remains very small compared to its core cement exposure at ~2%. We retain our EBITDA estimates for FY25e/FY263/FY27e as the new business stream will meaningfully contribute only from FY28e. Hence, we continue to assign 17x EV/EBITDA valuation to arrive at an unchanged TP of Rs 13,137. Maintain BUY.

Key changes

| , | | | |
|---|--------|------------|--|
| | Target | Rating | |
| | < ▶ | ∢ ▶ | |

| Ticker/Price | UTCEM IN/Rs 10,129 |
|------------------|--------------------|
| Market cap | US\$ 33.4bn |
| Free float | 40% |
| 3M ADV | US\$ 45.3mn |
| 52wk high/low | Rs 12,145/Rs 9,250 |
| Promoter/FPI/DII | 60%/15%/17% |
| | |

Source: NSE | Price as of 28 Feb 2025

Key financials

| FY24A | FY25E | FY26E |
|----------|--|--|
| 6,86,406 | 6,98,930 | 8,51,131 |
| 1,35,678 | 1,28,720 | 1,82,604 |
| 69,769 | 61,487 | 93,321 |
| 241.7 | 213.0 | 323.3 |
| 241.7 | 231.0 | 311.1 |
| 12.4 | 10.0 | 13.7 |
| 41.9 | 47.5 | 31.3 |
| 21.3 | 22.4 | 15.6 |
| 41.9 | (11.9) | 51.8 |
| | 6,86,406 1,35,678 69,769 241.7 241.7 12.4 41.9 21.3 | 6,86,406 6,98,930 1,35,678 1,28,720 69,769 61,487 241.7 213.0 241.7 231.0 12.4 10.0 41.9 47.5 21.3 22.4 |

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE





Key takeaways from the Conference call held on 28th February 2025 to update on the new investment

Ultratech Focus on Cement continues

UTCEM capacity is expected to be 182 mt by FY25 end and 209 mt by FY27.

Commentary on Wires and Cables Business

- UTCEM to foray into Cables and Wires business with a capex of Rs 18bn capex over FY25 and FY26 at Jhagadia, in Bharuch district in Gujarat. It is expected to be commissioned by December 2026 with a capacity of 3.5-4.0 mn kms.
- Total wires market grew at a CAGR 17.3% from FY19-FY24 to Rs 267 bn and the total cables market grew at a CAGR 12.2% from FY19-FY24 to Rs 710 bn. UTCEM expects the entire segment to grow at 13% over the next 5 years.
- Cables and Wires are non-discretionary spendings and UTCEM is likely to leverage existing relation with contractors and UBS Network.
- Increasing usage of wires due to higher consumption of white goods, consumer electronics etc provides healthy growth opportunities. Strong infrastructure growth such as metros, airports, railways provide impetus to infra-related demand. Newer areas such as renewable energy, EV charging infrastructure only assures future growth.
- UTCEM management indicated it will achieve an EBITDA margin similar to the industry and expects 25% ROCE.
- UTCEM has no plans of future capex as it will take 2031 to reach full capacity utilization of Jhagadia, Gujarat plant.
- The management indicated that the revenue target split will be 60% contributed by Wires and 40% Cables.
- There would be a new team in place containing both Specialist for manufacturing and marketing teams as the expertise and skill set required will be distinctive.
 However, general functions like Finance, Accounts and administration will continue from the existing man-power.
- Management expects to have minimal working capital/negative working capital.
- Product-design is completed, the engineering work has taken off, as mentioned above new team wherever required are in the process to be set up. The location is in close proximity of the copper source which is the key raw material source.



Valuation methodology

In our view, UTCEM's entry in the cable & wire business is a step towards providing one-stop building material solution from Cement, Putty, Paints and now into cable and wire business. The investment in the business is in-line or lower than the industry average as the capex (Rs9bn/year) is nearly half of the investment by the market leader. UTCEM management indicated no further investment till the asset investment is fully utilized till 2031 and further stressed no investment in any other diversified business.

There are limited entry barriers in the W & C business and UTCEM has an advantage of the backward integration with the readymade Aluminum and Copper business which is the key raw material required in the business. However, UTCEM will require to build the brand and the network in the B2B and B2C business which can be achieved by the company by expanding its existing footprints in the building division business.

UTCEM with its investment of Rs18bn will gain a market share of less than 5% (based on industry leader asset turnover of 4x). The size of the industry, export potential, shift of unorganised market to the organised market gives enough headroom to gain this market share. The return ratio profile of the C & W business is largely healthy (16-18%) though UTCEM has set an aggressive target of ~25%.

UTCEM will have to leverage its strong brand and network in the existing business to gain sizeable market share in a relatively lower time. The first full-fledged contribution is expected by FY28 (Q4FY27 at the earliest).

We have revised our PAT and EPS downwards by 5% and 6% for FY26e/FY27e to factor in additional depreciation impact (from the cement business). However, we retain our EBITDA estimates for FY25e/FY26e/FY27e as the new business stream will meaningfully contribute only from FY28e. Further, the capital allocation is at ~2% of the total business (focus on Cement continues) leaving no immediate impact on the current valuations (methodology). Hence, we continue to assign 17x EV/EBITDA valuation to arrive at an unchanged TP of Rs 13,137. Maintain BUY.

Fig 1 - Revised estimates

| (Do) | | New | | Old | | | Change (%) | | |
|--------------|----------|----------|----------|----------|----------|----------|------------|-------|-------|
| (Rs mn) | FY25E | FY26E | FY27E | FY25E | FY26E | FY27E | FY25E | FY26E | FY27E |
| Revenue | 6,98,930 | 8,51,131 | 9,69,109 | 6,98,930 | 8,51,131 | 9,69,109 | 0.0 | 0.0 | 0.0 |
| EBITDA | 1,28,720 | 1,82,604 | 2,24,974 | 1,28,720 | 1,82,604 | 2,24,974 | 0.0 | 0.0 | 0.0 |
| Adj PAT | 61,487 | 93,321 | 1,23,852 | 61,487 | 98,353 | 1,32,332 | 0.0 | (5.1) | (6.4) |
| Adj EPS (Rs) | 213.0 | 323.3 | 429.1 | 213.0 | 340.7 | 458.5 | 0.0 | (5.1) | (6.4) |

Source: BOBCAPS Research

Fig 2 - Key assumptions

| Parameter | FY24 | FY25E | FY26E | FY27E |
|------------------------|-------|-------|-------|-------|
| Volumes (mt) | 107.7 | 118.9 | 143.9 | 161.3 |
| Realisations (Rs/t) | 5,304 | 5,145 | 5,278 | 5,410 |
| Operating costs (Rs/t) | 5,201 | 4,883 | 4,726 | 4,692 |
| EBITDA/t (Rs/t) | 1,163 | 988 | 1,183 | 1,311 |

Source: Company, BOBCAPS Research




Fig 3 - Valuation summary

| Business (Rs mn) | FY27E |
|------------------------------|-----------|
| Target EV/EBITDA (x) | 17.0 |
| EBITDA | 2,24,974 |
| Target EV | 39,24,451 |
| Total EV | 39,24,451 |
| Net debt | (75,440) |
| Target market capitalisation | 39,99,892 |
| Target price (Rs/sh) | 13,137 |
| Weighted average shares (mn) | 288.7 |

Source: BOBCAPS Research Note: Valuations based on 1-year forward earnings (December 2027)

Fig 4 – EV/EBITDA band: Valuations to stay elevated for the largest cement company and top brand



Source: Company, Bloomberg, BOBCAPS Research

Fig 6 – EV/tonne: Replacement cost at valuations for industry leader






Fig 5 – EV/EBITDA 1Y fwd: Not withstanding current moderation, UTCEM poised to command higher premium



Source: Company, Bloomberg, BOBCAPS Research

Fig 7 – EV/tonne 1Y fwd: Valuations moderate leaves headroom for improvement



Source: Company, Bloomberg, BOBCAPS Research

Key risks

Key downside risks to our estimates are:

- Increasing competitive intensity and capacity addition may have a negative impact on cement sector pricing and could be detrimental for the industry and UTCEM.
- Delays in the implementation of capex plans could hamper growth.
- Energy cost spikes due to global uncertainties could dampen profitability.



Financials

| Income Statement Y/E 31 Mar (Rs mn) | FY23A | FY24A | FY25E | FY26E | FY27E |
|--|-------------------|---------------------|-----------------|-----------------|--------------------|
| Total revenue | 6,04,626 | 6,86,406 | 6,98,930 | 8,51,131 | 9,69,109 |
| EBITDA | 99,312 | 1,35,678 | 1,28,720 | 1,82,604 | 2,24,974 |
| Depreciation | (26,192) | (30,274) | (34,815) | (43,519) | (50,047) |
| EBIT | 80,014 | 1,02,548 | 1,03,342 | 1,50,039 | 1,87,297 |
| Net interest inc./(exp.) | (7,550) | (8,668) | (15,903) | (15,612) | (9,563) |
| Other inc./(exp.) | 6,894 | (2,855) | 9,438 | 10,954 | 12,370 |
| Exceptional items | 0,034 | (720) | 9,430 | 10,934 | 12,370 |
| EBT | 72,464 | 93,160 | 87,439 | 1,34,427 | 1,77,734 |
| Income taxes | (23,295) | (24,111) | (25,952) | (41,106) | (53,881) |
| Extraordinary items | (23,233) | (24,111) | (20,332) | (41,100) | (55,001) |
| Min. int./Inc. from assoc. | 0 | 0 | 0 | 0 | 0 |
| Reported net profit | 49,169 | 69,049 | 61.487 | 93,321 | 1,23,852 |
| Adjustments | 43,103 | (720) | 01,407 | 0 | 1,23,032 |
| Adjusted net profit | 49,169 | 69,769 | 61,487 | 93,321 | 1,23,852 |
| | | | | | |
| Balance Sheet Y/E 31 Mar (Rs mn) | FY23A | FY24A | FY25E | FY26E | FY27E |
| Accounts payables | 1,13,015 | 1,26,815 | 1,30,002 | 1,48,322 | 1,65,018 |
| Other current liabilities | 68,224 | 94,541 | 76,240 | 78,320 | 80,400 |
| Provisions | 7,779 | 8,878 | 9,393 | 9,946 | 10,542 |
| Debt funds | 1,01,440 | 80,873 | 1,62,906 | 1,03,957 | 73,113 |
| Other liabilities | 54,758 | 64,250 | 65,500 | 66,950 | 68,400 |
| Equity capital | 2,887 | 2,887 | 2,887 | 2,887 | 2,887 |
| Reserves & surplus | 5,26,482 | 5,88,065 | 6,38,746 | 7,19,909 | 8,31,603 |
| Shareholders' fund | 5,29,369 | 5,90,952 | 6,41,632 | 7,22,795 | 8,34,490 |
| Total liab. and equities | 8,74,584 | 9,66,309 | 10,85,673 | 11,30,290 | 12,31,963 |
| Cash and cash eq. | 72,802 | 28,680 | 57,703 | 88,360 | 1,54,208 |
| Accounts receivables | 32,422 | 34,965 | 37,518 | 48,020 | 57,331 |
| Inventories | 60,842 | 80,358 | 82,303 | 1,02,558 | 1,19,428 |
| Other current assets | 1,03,368 | 83,962 | 1,07,117 | 1,08,188 | 1,09,270 |
| Investments | 72,602 | 71,397 | 71,397 | 71,397 | 71,397 |
| Net fixed assets | 4,69,216 | 4,55,902 | 6,12,874 | 6,74,775 | 6,70,024 |
| CWIP | 38,072 | 1,85,035 | 90,000 | 10,000 | 23,000 |
| Intangible assets | 25,260 | 26,010 | 26,760 | 26,991 | 27,304 |
| Deferred tax assets, net | 0 | 0 | 0 | 0 | 27,004 |
| Other assets | 0 | 0 | 0 | 0 | 0 |
| Total assets | 8,74,584 | 9,66,309 | 10,85,673 | 11,30,290 | 12,31,963 |
| Cash Flows | | | | | |
| Y/E 31 Mar (Rs mn) | FY23A | FY24A | FY25E | FY26E | FY27E |
| Cash flow from operations | 99,263 | 1,47,378 | 55,300 | 1,27,416 | 1,67,458 |
| Capital expenditures | (55,845) | (1,64,673) | (97,503) | (25,651) | (58,610) |
| Change in investments | (17,905) | 42,860 | (26,000) | (30,000) | (30,000) |
| Other investing cash flows | 0 | 0 | 0 | 0 | 0 |
| Cash flow from investing | (73,750) | (1,21,813) | (1,23,503) | (55,651) | (88,610) |
| Equities issued/Others | 0 | 0 | 0 | 0 | 0 |
| Debt raised/repaid | (5,434) | (20,567) | 82,033 | (58,950) | (30,843) |
| Interest expenses | 8 | 9 | 10 | 10 | 10 |
| Dividends paid | (10,927) | (10,807) | (10,807) | (12,158) | (12,158) |
| zdorido pala | (1,579) | 3,342 | (10,007) | (12,130) | (12,100) |
| Other financing cash flows | | J,J ⊤ Z | U | U | U |
| Other financing cash flows Cash flow from financing | | (28 032) | 71 226 | (71 108) | (43 001) |
| Other financing cash flows Cash flow from financing Chg in cash & cash eq. | (17,940) 7,573 | (28,032) (2,466) | 71,226 3,023 | (71,108) 657 | (43,001) 35,847 |

| Per Share | =1/004 | =>/0.4.4 | =>/=== | =>/00= | =1/0== |
|-----------------------------------|---------|----------|---------|---------|---------|
| Y/E 31 Mar (Rs) | FY23A | FY24A | FY25E | FY26E | FY27E |
| Reported EPS | 170.3 | 239.2 | 213.0 | 323.3 | 429.1 |
| Adjusted EPS | 170.3 | 241.7 | 213.0 | 323.3 | 429.1 |
| Dividend per share | 37.9 | 32.0 | 32.0 | 36.0 | 36.0 |
| Book value per share | 1,833.9 | 2,047.3 | 2,222.9 | 2,504.1 | 2,891.0 |
| Valuations Ratios | | | | | |
| Y/E 31 Mar (x) | FY23A | FY24A | FY25E | FY26E | FY27E |
| EV/Sales | 4.8 | 4.2 | 4.1 | 3.3 | 3.0 |
| EV/EBITDA | 29.0 | 21.3 | 22.4 | 15.6 | 12.7 |
| Adjusted P/E | 59.5 | 41.9 | 47.5 | 31.3 | 23.6 |
| P/BV | 5.5 | 4.9 | 4.6 | 4.0 | 3.5 |
| DuPont Analysis | | | | | |
| Y/E 31 Mar (%) | FY23A | FY24A | FY25E | FY26E | FY27E |
| Tax burden (Net profit/PBT) | 67.9 | 74.1 | 70.3 | 69.4 | 69.7 |
| Interest burden (PBT/EBIT) | 90.6 | 91.5 | 84.6 | 89.6 | 94.9 |
| EBIT margin (EBIT/Revenue) | 13.2 | 14.9 | 14.8 | 17.6 | 19.3 |
| Asset turnover (Rev./Avg TA) | 71.9 | 74.6 | 68.1 | 76.8 | 82.0 |
| Leverage (Avg TA/Avg Equity) | 1.6 | 1.6 | 1.7 | 1.6 | 1.5 |
| Adjusted ROAE | 9.6 | 12.4 | 10.0 | 13.7 | 15.9 |
| Ratio Analysis | | | | | |
| Y/E 31 Mar | FY23A | FY24A | FY25E | FY26E | FY27E |
| YoY growth (%) | | | | | |
| Revenue | 21.6 | 13.5 | 1.8 | 21.8 | 13.9 |
| EBITDA | (9.2) | 36.6 | (5.1) | 41.9 | 23.2 |
| Adjusted EPS | (24.7) | 41.9 | (11.9) | 51.8 | 32.7 |
| Profitability & Return ratios (%) | (=) | | () | | |
| EBITDA margin | 16.2 | 19.5 | 18.1 | 21.2 | 22.9 |
| EBIT margin | 13.2 | 14.9 | 14.8 | 17.6 | 19.3 |
| Adjusted profit margin | 8.1 | 10.2 | 8.8 | 11.0 | 12.8 |
| Adjusted ROAE | 9.6 | 12.4 | 10.0 | 13.7 | 15.9 |
| ROCE | 12.0 | 14.4 | 12.9 | 17.0 | 20.0 |
| Working capital days (days) | .2.0 | | 0 | | |
| Receivables | 20 | 19 | 20 | 21 | 22 |
| Inventory | 37 | 43 | 43 | 44 | 4: |
| Payables | 80 | 83 | 82 | 80 | 80 |
| Ratios (x) | | | | | |
| Gross asset turnover | 1.0 | 1.1 | 0.8 | 0.9 | 1.0 |
| | 1.0 | 4.0 | | 0.0 | |

Adjusted debt/equity 0.2 0.1

Source: Company, BOBCAPS Research | Note: TA = Total Assets

1.4

10.6

1.0

11.8

1.3

6.5

0.3

1.5

9.6

0.1

1.7

19.6

0.1

Current ratio

Net interest coverage ratio



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: BOB Capital Markets Limited

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025

Brand Name: BOBCAPS

Trade Name: www.barodaetrade.com CIN: U65999MH1996GOI098009





Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): ULTRATECH CEMENT (UTCEM IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

ULTRATECH CEMENT



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as free date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.